600 West Chicago Avenue
Tempus is a technology company that has built an operating system to battle cancer. Tempus enables physicians to deliver personalized cancer care through its interactive analytical and machine learning platform. The company provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data.
Co-Founder and CEO: Eric Lefkofsky
President: Dr. Kevin White
Chief Medical Informatics Officer: Dr. Jonathan Silverstein
COO: Ryan Fukushima
Director of Laboratory Operations: Sam Bettis
Scientific Adviser: Dr. Arul Chinnaiyan
Please click here for Tempus' job opportunities.
21 articles with Tempus
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
9/5/2018On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial
The company announced a new research collaboration aimed at identifying which patients will respond positively to immunotherapy treatment, the next generation of cancer care.
Tempus xT analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer.
Tempus And The Oregon Health & Science University (OHSU) Knight Cancer Institute Collaborating On Personalized Medicine Data Initiative
Tempus And UC Davis Comprehensive Cancer Center Announce Personalized Medicine Partnership For Cancer Patients
Tempus Selected As Sequencing And Analytics Provider By The Prostate Cancer Clinical Trials Consortium For Phase II Clinical Trial
Tempus Selected By University of Virginia As Partner For Large Granular Lymphocyte Leukemia Research Project
Tempus Teams With Major Academic Medical Center To Advance Treatment Options For Patients Diagnosed With Aggressive Brain Cancer